NuCana (NCNA) Other Non-Current Liabilities (2017 - 2025)
NuCana's (NCNA) quarterly Other Non-Current Liabilities came in at $77149.6 in Q4 2025, up 50.27% year-on-year from $51340.1 in Q4 2024, and down 1.42% quarter-over-quarter from $78263.0 in Q3 2025.
NuCana (NCNA) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
NuCana has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $77149.6 for Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $77149.6, up 50.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $77149.6 (up 50.27% YoY), and the FY2025 annual result was $76473.6, up 49.56% from the prior year.
- Other Non-Current Liabilities came in at $77149.6 for Q4 2025 at NuCana, down from $78263.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 million in Q1 2023 to a low of $38979.0 in Q3 2024.
- The 5-year median for Other Non-Current Liabilities is $68141.2 (2023), against an average of $729175.5.
- Across the five-year window, Other Non-Current Liabilities jumped 7883.35% in 2023 and plunged 98.51% in 2024, its largest moves.
- NuCana's Other Non-Current Liabilities stood at $62008.5 in 2021, then surged by 7655.4% to $4.8 million in 2022, then sank by 98.5% to $71986.8 in 2023, then slipped by 28.68% to $51340.1 in 2024, then surged by 50.27% to $77149.6 in 2025.
- The last three Other Non-Current Liabilities figures came in at $77149.6 (Q4 2025), $78263.0 (Q3 2025), and $77374.6 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77,149.64 |
| Sep 30, 2025 | 78,263.00 |
| Jun 30, 2025 | 77,374.65 |
| Mar 31, 2025 | 50,380.02 |
| Dec 31, 2024 | 51,340.07 |
| Sep 30, 2024 | 38,979.00 |
| Jun 30, 2024 | 73,208.80 |
| Mar 31, 2024 | 73,574.05 |
| Dec 31, 2023 | 71,986.81 |
| Sep 30, 2023 | 73,467.72 |
| Jun 30, 2023 | 3.75 Mn |
| Mar 31, 2023 | 4.93 Mn |
| Dec 31, 2022 | 4.81 Mn |
| Sep 30, 2022 | 54,213.22 |
| Jun 30, 2022 | 57,928.45 |
| Mar 31, 2022 | 61,724.44 |
| Dec 31, 2021 | 62,008.49 |
| Sep 30, 2021 | 63,414.83 |
| Jun 30, 2021 | 64,295.50 |
| Mar 31, 2021 | 63,430.36 |